Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.

摘要: PURPOSEPatients with locally advanced inoperable non-small-cell lung cancer (NSCLC) have a poor clinical outcome. We conducted prospective study to evaluate the merit of chemotherapy administered concurrently hyperfractionated thoracic radiation therapy.PATIENTS AND METHODSSeventy-nine patients NSCLC were enrolled onto multicenter phase II trial concurrent chemoradiation therapy. Treatment consisted two cycles oral etoposide 100 mg/d (50 if body-surface area [BSA] 6 hours apart; total 69.6 Gy).RESULTSSeventy-six assessable Karnofsky performance status > or = 60 and adequate organ function who had received no prior therapy evaluated for outcome toxic effects. After minimum follow-up duration 21 months, 1- 2-year survival rates median 67%, 35%, 18.9 mon...